CN101489575B - Fkbp-l及其用途 - Google Patents

Fkbp-l及其用途 Download PDF

Info

Publication number
CN101489575B
CN101489575B CN2007800276683A CN200780027668A CN101489575B CN 101489575 B CN101489575 B CN 101489575B CN 2007800276683 A CN2007800276683 A CN 2007800276683A CN 200780027668 A CN200780027668 A CN 200780027668A CN 101489575 B CN101489575 B CN 101489575B
Authority
CN
China
Prior art keywords
fkbp
polypeptide
cells
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800276683A
Other languages
English (en)
Chinese (zh)
Other versions
CN101489575A (zh
Inventor
特拉西·罗布森
安德烈亚·瓦伦丁
马丁·奥鲁尔克
大卫·赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CN101489575A publication Critical patent/CN101489575A/zh
Application granted granted Critical
Publication of CN101489575B publication Critical patent/CN101489575B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
CN2007800276683A 2006-06-09 2007-06-08 Fkbp-l及其用途 Expired - Fee Related CN101489575B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0611405.2 2006-06-09
GBGB0611405.2A GB0611405D0 (en) 2006-06-09 2006-06-09 FKBP-L: A novel inhibitor of angiogenesis
PCT/GB2007/002107 WO2007141533A2 (en) 2006-06-09 2007-06-08 Fkbp-l and uses thereof

Publications (2)

Publication Number Publication Date
CN101489575A CN101489575A (zh) 2009-07-22
CN101489575B true CN101489575B (zh) 2013-08-28

Family

ID=36745574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800276683A Expired - Fee Related CN101489575B (zh) 2006-06-09 2007-06-08 Fkbp-l及其用途

Country Status (18)

Country Link
US (3) US9381228B2 (enExample)
EP (1) EP2040728B1 (enExample)
JP (1) JP5474535B2 (enExample)
CN (1) CN101489575B (enExample)
AU (1) AU2007255196B2 (enExample)
CA (1) CA2657947C (enExample)
CY (1) CY1116970T1 (enExample)
DK (1) DK2040728T3 (enExample)
ES (1) ES2548332T3 (enExample)
GB (1) GB0611405D0 (enExample)
HU (1) HUE028099T2 (enExample)
IL (1) IL195580A (enExample)
NZ (2) NZ600690A (enExample)
PL (1) PL2040728T3 (enExample)
PT (1) PT2040728E (enExample)
SI (1) SI2040728T1 (enExample)
WO (1) WO2007141533A2 (enExample)
ZA (1) ZA200810323B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
PT2332968T (pt) 2003-11-05 2016-08-17 Harvard College Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
GB0724393D0 (en) * 2007-12-14 2008-01-23 Univ Ulster Use of FKBPL gene to identify a cause of infertility
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
GB0908589D0 (en) * 2009-05-19 2009-06-24 Univ Belfast Assay method
WO2011008260A2 (en) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2920197B1 (en) 2012-09-26 2021-03-17 President and Fellows of Harvard College Proline-locked stapled peptides and uses thereof
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
EP2991665A4 (en) 2013-03-13 2016-11-09 Harvard College STACKED AND GRAFTED POLYPEPTIDES AND USES THEREOF
KR20160019547A (ko) 2013-06-14 2016-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 안정화된 폴리펩티드 인슐린 수용체 조절제
CN111620940A (zh) 2014-05-21 2020-09-04 哈佛大学的校长及成员们 Ras抑制肽和其用途
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
EP3402480B1 (en) 2016-01-11 2021-03-24 EpicentRx, Inc. Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
WO2017136312A1 (en) 2016-02-02 2017-08-10 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
CN109475598A (zh) * 2016-06-22 2019-03-15 阿尔麦克探索有限公司 眼部疾病的治疗
MX2019004280A (es) 2016-10-14 2019-09-18 Epicentrx Inc Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
EP3528831B1 (en) * 2016-10-19 2022-09-21 Royal College of Surgeons in Ireland Use of fkbp-l polypeptides and nucleic acids for the treatment of obesity
CN108362870A (zh) * 2017-01-27 2018-08-03 武汉三鹰生物技术有限公司 一种用于人fkbpl蛋白的酶联免疫检测及制备方法
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
CN111603567B (zh) * 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN113702632A (zh) * 2021-09-02 2021-11-26 深圳市光与生物科技有限公司 一种快速检测子痫前期的免疫层析检测卡及其制备方法与应用
CN114702564A (zh) * 2021-12-15 2022-07-05 江苏省人民医院（南京医科大学第一附属医院） 一种外泌体肽及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002569A2 (en) * 1999-07-06 2001-01-11 Incyte Genomics, Inc. Human immune response molecules
CN1281465A (zh) * 1998-10-09 2001-01-24 上海第二医科大学 人fk506结合蛋白(fkbp)
WO2002044418A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20060088836A1 (en) * 2002-04-24 2006-04-27 Jay Wohlgemuth Methods and compositions for diagnosing and monitoring transplant rejection

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194732A (en) 1960-10-03 1965-07-13 Neuhauser Irene Assisting healing of skin-denuded areas on the body with dried non-fibrous egg-shellmembrane products and compositions therefor
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JP3065628B2 (ja) * 1988-12-19 2000-07-17 三井化学株式会社 ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
AU648140B2 (en) 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
CZ343795A3 (en) * 1993-06-29 1996-07-17 Chiron Corp Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity
DK1486565T3 (da) * 1995-10-11 2008-03-10 Novartis Vaccines & Diagnostic Kombination af PDGF, KGF, IGF og IGFBP til sårheling
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
US6583168B1 (en) 1997-11-25 2003-06-24 Applera Corporation Sulfonated diarylrhodamine dyes
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2331382A1 (en) 1998-06-18 1999-12-23 Curagen Corporation Interaction of p27(kip1) with fkbp-12
JP4821031B2 (ja) 1999-04-13 2011-11-24 株式会社林原生物化学研究所 シアニン色素
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030125246A9 (en) * 2000-01-31 2003-07-03 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
PL215170B1 (pl) * 2001-06-22 2013-10-31 Hoffmann La Roche Sposób wytwarzania rozpuszczalnego kompleksu zawierajacego amyloidogenne bialko docelowe oraz bialko opiekuncze z klasy izomeraz peptydyloprolilowych
US6856185B2 (en) * 2001-10-23 2005-02-15 Arris International, Inc. Simple RMS to DC converter
US20040053388A1 (en) * 2002-01-03 2004-03-18 Eckert Jorg H. Detection of protein conformation using a split ubiquitin reporter system
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281465A (zh) * 1998-10-09 2001-01-24 上海第二医科大学 人fk506结合蛋白(fkbp)
WO2001002569A2 (en) * 1999-07-06 2001-01-11 Incyte Genomics, Inc. Human immune response molecules
WO2002044418A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20060088836A1 (en) * 2002-04-24 2006-04-27 Jay Wohlgemuth Methods and compositions for diagnosing and monitoring transplant rejection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Carl F. McAllister等.analysisi in Neisseria meningitidis and other Neisseria species of genes homologous to the FKBP immunophilin family.《molecular microbiology》.1993,第10卷(第1期), *
王耀辉.内皮细胞生长因子诱导大鼠内皮细胞增殖过程中FKBP12的表达.《第三军医大学学报》.2003,第25卷(第24期), *

Also Published As

Publication number Publication date
WO2007141533A2 (en) 2007-12-13
DK2040728T3 (en) 2015-10-26
US20160340402A1 (en) 2016-11-24
WO2007141533A3 (en) 2008-07-31
CA2657947C (en) 2017-11-21
IL195580A0 (en) 2011-08-01
AU2007255196B2 (en) 2013-10-03
US20160340401A1 (en) 2016-11-24
SI2040728T1 (sl) 2015-12-31
IL195580A (en) 2013-07-31
US20090192085A1 (en) 2009-07-30
NZ573425A (en) 2012-07-27
EP2040728B1 (en) 2015-09-02
US9381228B2 (en) 2016-07-05
GB0611405D0 (en) 2006-07-19
ZA200810323B (en) 2013-05-29
CY1116970T1 (el) 2017-04-05
NZ600690A (en) 2014-03-28
US10577406B2 (en) 2020-03-03
CN101489575A (zh) 2009-07-22
AU2007255196A1 (en) 2007-12-13
PL2040728T3 (pl) 2016-02-29
PT2040728E (pt) 2015-10-29
ES2548332T3 (es) 2015-10-15
CA2657947A1 (en) 2007-12-13
JP2009539367A (ja) 2009-11-19
EP2040728A2 (en) 2009-04-01
JP5474535B2 (ja) 2014-04-16
HUE028099T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
CN101489575B (zh) Fkbp-l及其用途
KR102694658B1 (ko) 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US8828925B2 (en) Etoposide and doxorubicin conjugates for drug delivery
KR20200100866A (ko) 항-전이성 요법에서 ａｘｌ 신호전달의 저해
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
MX2007005612A (es) Novedosas composiciones y metodos para el tratamiento de enfermedades inmuno relacionadas.
EP2413968B1 (en) Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
US9822363B2 (en) Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
US20030144236A1 (en) Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
US9193970B1 (en) Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
EP3716991A1 (en) Trpv6 inhibitors and combination therapies for treating cancers
EP2646473B1 (en) Fusion peptide comprising dhfas-1 domain and mmp substrate and use thereof for preventing and treating rheumatoid arthritis
CN110520144A (zh) 肽激酶抑制剂及其使用方法
WO2008150987A1 (en) Novel basement membrane associated fibulin fragments that function as tumor suppressors with anti-angiogenic activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130828

Termination date: 20200608